Bio-Techne Corporation has announced that Advanced Cell Diagnostics (ACD), a part of its Spatial Biology Division, has reached a significant milestone of over 10,000 peer-reviewed publications citing the use and benefits of RNAscope™ ISH technology. With over 50% of these publications released in the last three years, it is clear that ACD’s leadership in spatial biology applications is gaining global recognition and adoption.
As a pioneer in spatial biology, Bio-Techne offers a comprehensive range of over 50,000 unique RNAscope™ ISH probes for over 400 species. This enables biopharma and academic researchers to make groundbreaking discoveries, expedite the development of advanced therapies, and provide innovative diagnostics. The exceptional single-molecule sensitivity and precise subcellular resolution of RNAscope™ make it the most referenced spatial biology technology for RNA biomarkers in the industry. The 10,000 scientific publications span various fields such as cancer, neuroscience, immunology, infectious diseases, cell and gene therapy, and regenerative medicine.
Matt McManus, President of Bio-Techne’s Diagnostics & Genomics Segment, expressed excitement about the milestone achievement of 10,000 publications referencing RNAscope™ ISH technology. He conveyed gratitude for the confidence shown by the scientific community in utilizing RNAscope™ to uncover new spatial insights and facilitate significant advancements in diverse disease areas.
